Presented today at #ECO2026 The SURMOUNT-MAINTAIN trial found that continuing tirzepatide at the maximum tolerated dose maintained bodyweight reduction and health-related benefits in adults with obesity
Gupta , Consultant Physician, Delhi
Novo's immediate counter: aggressive savings cards showing "very good uptake." But here's the policy pressure point: Once three generics hit the Canadian market, regulations mandate a 65% cut to Novo's list price
Monthly growth rates were 83.9% for OZEMPIC, 119.2% for WEGOVY , 84.8% for RYBELSUS, 12.9% for ADLYXIN, 78.8% for TRULICITY, and 254.3% for MOUNJARO
[57] found increased oxidative stress and tissue damage supplementation with vitamin C and a cysteine derivative n-acytylcysteine (NAC), compared to a placebo
Without a comprehensive treatment plan that includes balanced nutrition, physical activity, and strategies to preserve and increase skeletal muscle mass, you might be losing more than just fatand increasing your chances of weight regain down the road